Neuro imaging niche IXICO specializes in neurodegenerative biomarker imaging for Alzheimer’s, Parkinson’s, Huntington’s and rare diseases, presenting a targeted opportunity for CRO services in CNS clinical trials and biomarker analytics.

End-to-end iCRO As a 20-year, end-to-end imaging CRO, IXICO can offer integrated study design, data acquisition, analysis, and reporting, appealing to sponsors seeking streamlined CNS trial workflows.

Revenue resilience Recent news suggests revenue guidance stability and forecast upgrades driven by contract wins and a growing client base, indicating a potential for expansion engagements and higher lifetime value with existing customers.

Tech stack leverage IXICO’s use of AWS, Azure DevOps, Docker and cloud-based analytics enables scalable, secure data processing; selling these capabilities to sponsors prioritizing cloud-based, compliant imaging workflows could open upsell or cross-sell opportunities.

Strategic outreach With a mid-sized team and a focus on neuroimaging biomarkers, targeting mid to late-stage CNS programs and companies expanding into biomarker-driven trials could yield high conversion with tailored iCRO and biomarker analytics offerings.